Journal article
Ketamine plus midazolam compared to midazolam infusion for the management of refractory status epilepticus
Clinical neurology and neurosurgery, v 246, 108592
Nov 2024
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Data for the use of ketamine (Ket) in treatment of refractory and super-refractory status epilepticus (RSE, SRSE) is lacking despite its widespread growing use. We examined the efficacy of ketamine plus midazolam (MDZ) infusions for treating RSE versus midazolam alone. We hypothesized that ketamine initiation would result in earlier seizure termination.
Data was obtained from electronic health records (EHR) of adult patients who received intravenous anesthetic agents for RSE in our neurointensive care unit. Two cohorts were identified. The MDZ cohort received midazolam as the only intravenous anesthetic agent for RSE. The Ket+MDZ cohort received midazolam infusion followed by ketamine infusion. The primary outcomes were time from midazolam infusion start to SE end in both cohorts, and time from ketamine infusion start (Ket Start) to SE end in the Ket+MDZ cohort versus midazolam infusion start (MDZ start) to SE end in the MDZ cohort.
73 patients were included (MDZ cohort n=17, Ket + MDZ cohort n=56). Cohorts did not differ significantly in age, sex, race, RSE etiology, or GCS on admission. Mean APACHE II score was higher in the Ket +MDZ cohort (26 ± 7.32 SD) versus the MDZ cohort (22 ± 5.89 SD)(P=.015). In survival analyses, cohorts did not differ significantly in time from midazolam start to SE end (HR=0.965, 95 % CI=0.556–1.673, P=.899; median [IQR]: MDZ: 25 h [4.5–58]; Ket+MDZ: 21.5 h [IQR 13.5–49]). Time from Ket start (Ket+MDZ group) versus time from MDZ start (MDZ group) to SE end was significantly shorter in the Ket+MDZ cohort (HR=1.895, 95 % CI=1.083–3.314, P=.025). The pattern of results was similar when including APACHE II and MDZ maximum dosage as covariates.
Time to SE end was significantly shorter after addition of ketamine infusion to midazolam infusion, versus after initiation of midazolam infusion monotherapy. Patients with higher disease severity favored Ket+MDZ. Randomized controlled trials are warranted in determining optimal anesthetics in RSE and SRSE.
•We studied the use of ketamine infusion for the treatment of status epilepticus.•Midazolam infusion was compared to midazolam plus ketamine infusions.•Addition of ketamine might result in earlier seizure termination.•Addition of ketamine might reduce the duration of status epilepticus.
Metrics
22 Record Views
Details
- Title
- Ketamine plus midazolam compared to midazolam infusion for the management of refractory status epilepticus
- Creators
- Elizabeth W. Fletman - Thomas Jefferson University HospitalSean Cleymaet - HonorHealthAmanda Salvatore - Thomas Jefferson University HospitalKathryn Devlin - Drexel UniversityAllyson Pickard - Thomas Jefferson University HospitalSyed Omar Shah - Thomas Jefferson University Hospital
- Publication Details
- Clinical neurology and neurosurgery, v 246, 108592
- Publisher
- Elsevier
- Number of pages
- 8
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Psychological and Brain Sciences (Psychology)
- Web of Science ID
- WOS:001335610900001
- Scopus ID
- 2-s2.0-85206329425
- Other Identifier
- 991021930913804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Clinical Neurology
- Surgery